Skip to content
value.today

Model Medicines, Inc.

Formerly Repurpose.AI, Inc.

Total raised
$23 M
3 rounds on record
Latest round
$5 M
Oct 2026
First round on record
Sep 2024
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Model Medicines, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2026$5 MNo. 3$2 to $10 million

Model Medicines, Inc.: Raise no. 3, Oct 2026

Investors in this round

37 investors had bought by the notice of Oct 21, 2026: 37 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $8 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Haders · Executive Officer · President

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel Haders, President. Source: SEC Form D, newest notice filed Oct 21, 2026. Read the notice at the SEC.

equitySEC
Oct 2025$3 MNo. 2$2 to $10 million

Model Medicines, Inc.: Raise no. 2, Oct 2025

Investors in this round

10 investors had bought by the notice of Nov 14, 2025: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $5 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Haders · Executive Officer · President

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel Haders, President. Source: SEC Form D, newest notice filed Nov 14, 2025. Read the notice at the SEC.

equitySEC
Sep 2024$15 MNo. 1$10 to $50 million

Model Medicines, Inc.: Raise no. 1, Sep 2024

Investors in this round

43 investors had bought by the notice of Oct 15, 2024: 43 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daniel Haders · Executive Officer, Director
  • Kip Quackenbush · Executive Officer, Director
  • Marlon Evans · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daniel Haders, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 15, 2024. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Model Medicines, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2026).

    SEC Form D · Oct 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2026

That is all the official record says: Model Medicines, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Model Medicines, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 43 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Model Medicines, Inc.
NameRoleNamed in
Daniel HadersPresidentNov 2025
Kip QuackenbushExecutive officerOct 2024
Marlon EvansExecutive officerOct 2024
Daniel HadersDirectorOct 2024
Kip QuackenbushDirectorOct 2024
Marlon EvansDirectorOct 2024